Dr. Lal PathLabs Q1 FY27 Results: Revenue Rises 19% YoY, PAT Grows 27%
Dr. Lal PathLabs reported a strong Q1 FY27 with double-digit growth in revenue, profit, and EBITDA, supported by healthy diagnostic volumes and improved operating margins.
Dr. Lal PathLabs Q1 Results 2027: Dr. Lal PathLabs delivered a strong Q1 FY27 performance, with revenue growing 19% year-on-year and EBITDA rising nearly 29%. Improved operating efficiency supported margin expansion, while PAT and EPS increased over 27%, reflecting healthy demand across the company's diagnostics business.
Dr. Lal PathLabs Q1 Results 2027: On 24 July, Dr. Lal PathLabs reported a strong performance in the first quarter of FY27, supported by healthy growth in diagnostic volumes and improved operating efficiency. Revenue from Operations increased 19.10% year-on-year to ₹797.70 crore, while Profit After Tax (PAT) rose 27.24% YoY to ₹170.50 crore, with margins also improving.
Dr. Lal PathLabs Q1 FY2027 Results Highlights
-
Revenue from Operations stood at ₹797.70 crore in Q1 FY27, registering 19.10% YoY growth from ₹669.80 crore in Q1 FY26. Compared with ₹702.70 crore in Q4 FY26, revenue increased 13.52%.
-
Total Revenue came in at ₹829.60 crore, up 18.87% YoY from ₹697.90 crore and 14.16% from ₹726.70 crore in Q4 FY26.
-
EBITDA (excluding Other Income) stood at ₹247.50 crore, compared with ₹192.30 crore in Q1 FY26, reflecting 28.71% YoY growth. Compared with ₹186.80 crore in Q4 FY26, EBITDA increased 32.49%.
-
EBITDA Margin improved to 31.03%, compared with 28.71% in Q1 FY26 and 26.58% in Q4 FY26, expanding by 232 basis points YoY and 444 basis points from Q4 FY26.
-
Profit After Tax (PAT) stood at ₹170.50 crore, compared with ₹134.00 crore in Q1 FY26, reflecting 27.24% YoY growth. Compared with ₹132.20 crore in Q4 FY26, PAT increased 28.97%.
-
PAT Margin improved to 21.37%, compared with 20.01% in Q1 FY26 and 18.81% in Q4 FY26, expanding by 137 basis points YoY and 256 basis points from Q4 FY26.
-
Earnings Per Share (EPS) stood at ₹10.15, compared with ₹7.94 in Q1 FY26, registering 27.83% YoY growth. Compared with ₹7.86 in Q4 FY26, EPS increased 29.13%.
|
Metric |
Q1 FY27 |
Q4 FY26 |
QoQ % |
Q1 FY26 |
YoY % |
|---|---|---|---|---|---|
|
Revenue from Operations (₹ Cr) |
797.70 |
702.70 |
13.52% |
669.80 |
19.10% |
|
Total Revenue (₹ Cr) |
829.60 |
726.70 |
14.16% |
697.90 |
18.87% |
|
EBITDA (Ex. Other Income) (₹ Cr) |
247.50 |
186.80 |
32.49% |
192.30 |
28.71% |
|
EBITDA Margin |
31.03% |
26.58% |
+444 bps |
28.71% |
+232 bps |
|
PAT (₹ Cr) |
170.50 |
132.20 |
28.97% |
134.00 |
27.24% |
|
PAT Margin |
21.37% |
18.81% |
+256 bps |
20.01% |
+137 bps |
|
EPS (₹) |
10.15 |
7.86 |
29.13% |
7.94 |
27.83% |
Source: Dr. Lal PathLabs Q1 FY27 Financial Results.
READ THIS ALSO: Mphasis Q1 FY27 Results
Dr. Lal PathLabs Dividend and Share Price Today
Dr. Lal PathLabs' board declared an interim dividend of ₹5 per equity share (50% on the face value of ₹10) for FY27. The record date has been fixed as July 30, 2026, and the dividend will be paid within 30 days of its declaration.
As of 24 July, 3:00 PM
Dr. Lal PathLabs share price is trading at 1714.70 (-1.64%) on 23 July 2026. The stock is up 13.69% year-to-date and up 10.91% in one year from 24 July 2025 to 24 July 2026